AVIDBIOTICS CORPORATION

Company Information

Company Name
AVIDBIOTICS CORPORATION
Address
100 Kimball Way
SOUTH SAN FRANCISCO, CA, -
Phone
n/a
URL
n/a
DUNS
163439511
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$3,158,315.00
6
SBIR Phase II
$1,073,420.00
1
Chart code to be here

Award List

  1. Create, evaluate and develop pre-clinically an engineered R-type pyocin to specif

    Amount: $512,103.00

    DESCRIPTION (provided by applicant): Acinetobacter baumannii (A. baumannii) is a human pathogen responsible for recent increases in nosocomial infections of both military and civilian populations. Fur ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Targeted soluble MICA molecules to recruit innate immunity cells to kill specific

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The overall objective of this proposal is to develop a platform that broadly enables the generation of a new class of anti-viral therapeutics that recruit and acti ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. HOST RANGE DIVERSITY OF BACTERIOPHAGE FOR Y. PESTIS

    Amount: $494,982.00

    DESCRIPTION (provided by applicant): Yersinia pestis, the bacterium responsible for plague, is a Category A pathogen, a significant biowarfare agent. If weaponized, it can easily gain direct access to ...

    SBIR Phase I 2006 Department of Health and Human Services
  4. Engineered R-type pyocins as bactericidal agents against E.coli O157:H7

    Amount: $635,152.00

    DESCRIPTION (provided by applicant): Our overall Goal is to develop our bactericidal R-type pyocin targeting E.coli O157:H7, as a specific therapeutic against infection and contamination. Enterohemorr ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. Non-clinical Development of Bactericidal Proteins Targeting Plague

    Amount: $1,073,420.00

    DESCRIPTION (provided by applicant): In our Phase 1 project we have developed R-type pyocins, targetable bactericidal proteins, that kill the plague bacterium, Yersinia pestis, in vitro and are not se ...

    SBIR Phase II 2009 Department of Health and Human Services
  6. TARGETABLE BACTERICIDAL PROTEINS TO SPECIFICALLY KILL CLOSTRIDIUM DIFFICILE BACTE

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The ultimate goal of this proposal and any subsequent phase II proposal is to develop a unique protein agent to prevent Clostridium difficile associated diseases i ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. DIVERSIFYING MICA TO CREATE TARGETED ADAPTERS TO RECRUIT AND ACTIVATE NK CELLS TO

    Amount: $316,078.00

    DESCRIPTION (provided by applicant): Monoclonal antibodies targeting tumor associated antigens (TAA's) have since 1997, provided safe and efficacious human cancer therapeutics. More recently, bis ...

    SBIR Phase I 2013 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government